The vaginal microenvironment in asymptomatic versus symptomatic bacterial vaginosis
无症状与有症状细菌性阴道病的阴道微环境
基本信息
- 批准号:10666011
- 负责人:
- 金额:$ 27.82万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-01 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:16S ribosomal RNA sequencingAffectAgeAmericanAnaerobic BacteriaAntibiotic TherapyAreaAtopobium vaginaeAutomobile DrivingBacteriaBacterial VaginosisBehavioralBiogenic AminesBiological Response Modifier TherapyBlack raceChlamydiaClinical ResearchClinical TreatmentCohort StudiesDataData SourcesDatabasesDevelopmentEpidemiologyFeminineFundingFutureGrantGuidelinesHIVHIV riskHIV-1HygieneIL6 geneIL8 geneImmunologic FactorsImmunologicsInflammationInflammation MediatorsInflammatoryInterferon Type IIInterleukin-1 betaIrrigationIsomerismK-Series Research Career ProgramsLactic acidLactobacillusLeadLongitudinal StudiesMediatingMethodsNIH Program AnnouncementsNational Institute of Allergy and Infectious DiseaseOutputPathogenesisPatientsPerceptionPilot ProjectsPredispositionPublishingRecommendationRecurrenceReproductive HealthResearchResearch Project GrantsRiskSamplingSexually Transmitted DiseasesSmokingSymptomsTaxonomyTestingUncertaintyUnited States National Institutes of HealthVaginaWomanWomen&aposs Healthadverse outcomebiobehaviorcareer developmentcervicovaginalcondomscytokinedesigndysbiosiseffective therapyepidemiology studyhormonal contraceptionimprovedinfection riskmetabolomemetabolomicsmicrobiotanegative affectnovelperceived stresspreventprogramsrRNA Genesrandomized trialreproductiveresponsesecondary analysissymptom treatmentsymptomatologyvaginal microbiomevaginal microbiota
项目摘要
Bacterial vaginosis (BV), which is characterized by a dysbiotic vaginal microbiota low in Lactobacillus species,
affects nearly 30% of U.S. women; the majority (55%) are asymptomatic (aBV). Guidelines currently
recommend testing and treatment only for symptomatic BV (sBV). BV (a composite variable with aBV and
symptomatic BV [sBV]) has been associated with an increased risk of sexually transmitted infections (STIs)
and HIV acquisition. Although studies to distinguish the differential risk of incident STI or HIV between women
with aBV and sBV have not been published, preliminary data from our group suggests that aBV is strongly
associated with incident STI and a published pilot study of BV suppressive therapy in women with aBV
indicated a decrease in chlamydia cases. To date, enthusiasm for research on or clinical treatment of aBV has
been limited, primarily by lack of data on aBV risks and perceptions of low efficacy of currently available BV
treatments. However, while BV treatment is challenging, approximately 50% of women with sBV taking
currently available therapies do achieve lasting cure. Moreover, novel, more effective therapies for BV are on
the horizon: a recent high-profile randomized trial of Lactin V, a L. crispatus intravaginal live biotherapeutic
product, showed reduced BV recurrence13. As new, better treatments for sBV become available, it is critical to
determine whether women with aBV should also be treated, in order to prevent sequelae such as STI or HIV
acquisition. If the vaginal microenvironment is shown to be identical in women with sBV and aBV, this will be
an important initial step demonstrating that aBV is a condition that should not be ignored, and will galvanize
further studies to define aBV, STI and HIV risk, and advance treatment. In a large epidemiologic study of over
300 women, our specific aims are to assess whether women with aBV and sBV differ in two broad areas (1)
biobehavioral factors and (2) the vaginal microenvironment, including factors associated with HIV and STI
acquisition risk (vaginal microbiota, key metabolites and soluble mediators of inflammation). This is a
secondary analysis leveraging existing data from a previously funded study (NIAID R01-AI116799, PI:
Brotman) for which 16S rRNA gene amplicon, metabolomic, and immunologic profiles have already been
generated from cervicovaginal lavage samples collected in the NIH's Longitudinal Study of Vaginal Flora.
Information gained through this proposed study will provide foundational data to better define aBV, and to
determine whether future studies to define the risk of HIV and STI acquisition associated with aBV, or studies
of aBV treatment as a method to prevent HIV and STIs are needed. This resubmission application is in
response to a program announcement (PAR-20-291) which is designed for Exploratory and Developmental
Research Grant Program for NIAID K-award Recipients. It will provide career development for the PI to
transition to research independence with a highly feasible and valuable clinical research project focused on the
vaginal microbiome and women's health.
细菌性阴道病(BV),其特征是阴道微生物群中乳杆菌种类较少,
影响到近30%的美国女性;大多数(55%)是无症状(ABV)。目前的指导方针
建议仅对有症状的BV(SBV)进行检测和治疗。BV(ABV和ABV的复合变量
有症状的BV[SBV]与性传播感染(STI)的风险增加有关
和艾滋病病毒的获取。尽管有研究区分女性之间发生性传播感染或艾滋病毒的不同风险
在ABV和SBV尚未发表的情况下,我们小组的初步数据表明,ABV是强有力的
与性传播感染事件和一项已发表的对ABV女性进行BV抑制治疗的先导性研究
显示衣原体感染病例有所减少。到目前为止,对ABV的研究或临床治疗的热情已经
受到限制,主要是因为缺乏关于ABV风险的数据,以及对现有BV疗效较低的看法
治疗。然而,尽管BV治疗具有挑战性,但大约50%患有SBV的女性服用
目前可用的治疗方法确实可以实现持久的治愈。此外,针对BV的新的、更有效的治疗方法正在进行中
地平线:最近一项备受瞩目的LACTIN V随机试验,一种经阴道活体治疗的皱纹夜蛾
产品显示BV复发率降低13。随着新的、更好的SBV治疗方法的出现,至关重要的是
确定患有ABV的妇女是否也应该接受治疗,以防止STI或HIV等后遗症
收购。如果SBV和ABV女性的阴道微环境被证明是相同的,这将是
重要的第一步表明ABV是一种不应被忽视的情况,并将激励
进一步研究以确定ABV、STI和HIV风险,并推进治疗。在一项大规模的流行病学研究中
300名女性,我们的具体目标是评估患有ABV和SBV的女性是否在两个广泛的领域存在差异(1)
生物行为因素和(2)阴道微环境,包括与艾滋病毒和性传播感染有关的因素
获得性风险(阴道微生物区系、关键代谢物和炎症的可溶性介质)。这是一个
利用先前资助研究的现有数据进行二次分析(NIAID R01-AI116799,PI:
其16S rRNA基因扩增子、代谢组学和免疫学图谱已经被
由美国国立卫生研究院阴道菌群纵向研究中收集的宫颈阴道灌洗液样本产生。
通过这项拟议研究获得的信息将为更好地定义ABV提供基础数据,并
确定未来确定与ABV相关的HIV和STI感染风险的研究,还是研究
需要将ABV治疗作为预防艾滋病毒和性传播感染的一种方法。此重新提交的申请在
对专为探索和开发而设计的计划公告(PAR-20-291)的回应
为NIAID K奖获得者提供的研究资助计划。它将为PI提供职业发展,以
通过高度可行和有价值的临床研究项目过渡到研究独立性,重点是
阴道微生物群与女性健康。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Susan Anne Tuddenham其他文献
Susan Anne Tuddenham的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Susan Anne Tuddenham', 18)}}的其他基金
The rectal microbiome and incident rectal sexually transmitted infections
直肠微生物组和直肠性传播感染事件
- 批准号:
10349502 - 财政年份:2021
- 资助金额:
$ 27.82万 - 项目类别:
Dysbiosis, Recurrent Bacterial Vaginosis and the Vaginal Microbiome
菌群失调、复发性细菌性阴道病和阴道微生物组
- 批准号:
9297211 - 财政年份:2016
- 资助金额:
$ 27.82万 - 项目类别:
Dysbiosis, Recurrent Bacterial Vaginosis and the Vaginal Microbiome
菌群失调、复发性细菌性阴道病和阴道微生物组
- 批准号:
9163096 - 财政年份:2016
- 资助金额:
$ 27.82万 - 项目类别:
相似海外基金
Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
- 批准号:
495182 - 财政年份:2023
- 资助金额:
$ 27.82万 - 项目类别:
Investigating how alternative splicing processes affect cartilage biology from development to old age
研究选择性剪接过程如何影响从发育到老年的软骨生物学
- 批准号:
2601817 - 财政年份:2021
- 资助金额:
$ 27.82万 - 项目类别:
Studentship
RAPID: Coronavirus Risk Communication: How Age and Communication Format Affect Risk Perception and Behaviors
RAPID:冠状病毒风险沟通:年龄和沟通方式如何影响风险认知和行为
- 批准号:
2029039 - 财政年份:2020
- 资助金额:
$ 27.82万 - 项目类别:
Standard Grant
Neighborhood and Parent Variables Affect Low-Income Preschool Age Child Physical Activity
社区和家长变量影响低收入学龄前儿童的身体活动
- 批准号:
9888417 - 财政年份:2019
- 资助金额:
$ 27.82万 - 项目类别:
The affect of Age related hearing loss for cognitive function
年龄相关性听力损失对认知功能的影响
- 批准号:
17K11318 - 财政年份:2017
- 资助金额:
$ 27.82万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9320090 - 财政年份:2017
- 资助金额:
$ 27.82万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
10166936 - 财政年份:2017
- 资助金额:
$ 27.82万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9761593 - 财政年份:2017
- 资助金额:
$ 27.82万 - 项目类别:
How age dependent molecular changes in T follicular helper cells affect their function
滤泡辅助 T 细胞的年龄依赖性分子变化如何影响其功能
- 批准号:
BB/M50306X/1 - 财政年份:2014
- 资助金额:
$ 27.82万 - 项目类别:
Training Grant
Inflamm-aging: What do we know about the effect of inflammation on HIV treatment and disease as we age, and how does this affect our search for a Cure?
炎症衰老:随着年龄的增长,我们对炎症对艾滋病毒治疗和疾病的影响了解多少?这对我们寻找治愈方法有何影响?
- 批准号:
288272 - 财政年份:2013
- 资助金额:
$ 27.82万 - 项目类别:
Miscellaneous Programs